|
CENPQ expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 3.50400042314902E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
8.40170000238061E-08 |
| Normal-vs-Stage2 |
1.60340000054937E-07 |
| Normal-vs-Stage3 |
1.62950000159867E-08 |
| Normal-vs-Stage4 |
1.09059999919836E-08 |
| Stage1-vs-Stage2 |
6.598300E-02 |
| Stage1-vs-Stage3 |
3.684000E-02 |
| Stage1-vs-Stage4 |
1.609850E-02 |
| Stage2-vs-Stage3 |
8.393200E-01 |
| Stage2-vs-Stage4 |
6.763000E-01 |
| Stage3-vs-Stage4 |
5.165600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
7.11730008262634E-10 |
| Normal-vs-AfricanAmerican |
3.983200E-04 |
| Normal-vs-Asian |
1.787380E-04 |
| Caucasian-vs-AfricanAmerican |
9.550400E-01 |
| Caucasian-vs-Asian |
4.355600E-01 |
| AfricanAmerican-vs-Asian |
5.957000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
7.3554995427827E-10 |
| Normal-vs-Female |
6.36069996673427E-09 |
| Male-vs-Female |
1.769210E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
4.44560000001371E-06 |
| Normal-vs-Age(41-60Yrs) |
2.2963999590786E-09 |
| Normal-vs-Age(61-80Yrs) |
6.35199670639963E-11 |
| Normal-vs-Age(81-100Yrs) |
4.948300E-02 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
3.100200E-02 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
4.219400E-04 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
9.993000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
7.786200E-02 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
4.890000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
1.727620E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
9.483600E-01 |
| Classical-VS-Follicular |
8.623800E-02 |
| Classical-VS-Other |
8.649000E-01 |
| Classical-VS-Normal |
9.80799996774806E-09 |
| Tall-VS-Follicular |
3.549000E-01 |
| Tall-VS-Other |
8.747800E-01 |
| Tall-VS-Normal |
8.406700E-04 |
| Follicular-VS-Other |
5.016400E-01 |
| Follicular-VS-Normal |
7.73899999639838E-08 |
| Other-VS-Normal |
7.655700E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
1.04260000632905E-09 |
| Normal-vs-N1 |
9.1439000005078E-07 |
| N0-vs-N1 |
7.505600E-01 |
|
|
